Stocks Overview

LAST PRICE
7.4400
TODAY'S CHANGE (%)
0.0000 (0.0000%)

Bid / Lots
7.2800/ 1
Ask / Lots
8.8600/ 2
Open / Previous Close
0.0000 / 7.4400
Day Range
---
52 Week Range
Low 1.6100
High 10.2400
Volume
11
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TSX Comp
TSX Venture
DJIA
S&P 500
NASDAQ

Price Comparison Graph. See accessible table below

1 Day Comparison Chart Accessibility Table. Thursday's close: 7.58
Time	Volume	MESO
09:32 ET	1016	7.46
09:34 ET	100	7.645
09:41 ET	100	7.65
09:45 ET	1000	7.6661
09:48 ET	22536	7.475
09:52 ET	295	7.44
09:56 ET	100	7.43
10:03 ET	2063	7.4
10:06 ET	1000	7.47
10:10 ET	200	7.42
10:14 ET	200	7.42
10:15 ET	2200	7.42
10:17 ET	2300	7.41
10:21 ET	200	7.41
10:24 ET	511	7.4663
10:28 ET	400	7.415
10:30 ET	400	7.4371
10:32 ET	7174	7.4
10:35 ET	100	7.4
10:42 ET	284	7.4
10:46 ET	182	7.4
10:50 ET	682	7.4
10:51 ET	2753	7.4
10:57 ET	200	7.4
11:00 ET	300	7.4
11:06 ET	300	7.4
11:15 ET	500	7.4
11:18 ET	100	7.41
11:20 ET	12305	7.34
11:22 ET	200	7.34
11:24 ET	136	7.3545
11:26 ET	1249	7.355
11:31 ET	300	7.34
11:33 ET	100	7.34
11:36 ET	1750	7.3201
11:38 ET	499	7.325
11:42 ET	500	7.3
11:45 ET	506	7.3245
11:51 ET	3391	7.33
11:54 ET	3514	7.32
12:03 ET	634	7.3
12:12 ET	3672	7.29
12:14 ET	540	7.3303
12:16 ET	100	7.31
12:18 ET	418	7.31
12:20 ET	561	7.3155
12:21 ET	100	7.29
12:23 ET	1200	7.3
12:25 ET	200	7.3319
12:30 ET	10910	7.28
12:34 ET	500	7.3
12:38 ET	300	7.32
12:39 ET	100	7.315
12:43 ET	341	7.31
12:50 ET	1212	7.345
12:54 ET	200	7.31
12:57 ET	100	7.31
12:59 ET	1190	7.3673
01:08 ET	400	7.33
01:10 ET	400	7.3
01:15 ET	148	7.3
01:21 ET	200	7.28
01:24 ET	469	7.28
01:26 ET	584	7.29
01:30 ET	500	7.29
01:32 ET	100	7.285
01:33 ET	1160	7.28
01:35 ET	300	7.3
01:37 ET	355	7.295
01:39 ET	100	7.29
01:44 ET	227	7.29
01:51 ET	200	7.3
01:55 ET	100	7.3
02:00 ET	200	7.3
02:02 ET	263	7.3
02:06 ET	100	7.29
02:11 ET	300	7.29
02:15 ET	590	7.3
02:18 ET	550	7.32
02:20 ET	363	7.3
02:26 ET	194	7.3
02:27 ET	200	7.3
02:29 ET	200	7.295
02:31 ET	205	7.3
02:33 ET	202	7.3
02:36 ET	1387	7.3
02:45 ET	600	7.3
02:47 ET	800	7.2915
02:49 ET	100	7.29
02:51 ET	285	7.29
02:58 ET	367	7.2932
03:00 ET	100	7.33
03:05 ET	800	7.32
03:09 ET	100	7.29
03:12 ET	300	7.32
03:14 ET	100	7.33
03:18 ET	5100	7.32
03:20 ET	100	7.33
03:21 ET	1302	7.315
03:25 ET	853	7.295
03:27 ET	200	7.29
03:30 ET	200	7.295
03:32 ET	500	7.295
03:34 ET	1000	7.295
03:36 ET	1900	7.295
03:38 ET	2980	7.3
03:41 ET	920	7.29
03:43 ET	1504	7.3
03:45 ET	1900	7.3
03:48 ET	649	7.29
03:50 ET	20444	7.365
03:52 ET	2459	7.43
03:54 ET	300	7.46
03:56 ET	100	7.44
03:57 ET	104	7.44
03:59 ET	1632	7.44

Data delayed at least 15 minutes.

Yesterday
- Mesoblast Corporate Presentation at Investor Conference, from 8 hours ago by Dow Jones
  8 hours ago by Dow Jones

0 New Today

Industry Peers Overview Table
Company sortable	Market Cap sortable	P/E Ratio (TTM) sortable	EPS Growth (5yr) sortable
United StatesMESO Mesoblast Ltd	843.1M	-5.2x	---
United StatesZNTL Zentalis Pharmaceuticals Inc	843.6M	-3.5x	---
United StatesIRON Disc Medicine Inc	839.3M	-10.1x	---
United StatesTYRA Tyra Biosciences Inc	852.2M	-9.6x	---
United StatesPRAX Praxis Precision Medicines Inc	811.9M	-3.0x	---
United StatesSPRY ARS Pharmaceuticals Inc	860.4M	-17.1x	---
As of 2024-06-03

Mesoblast Limited is an Australia-based is developing a range of late-stage product candidates derived from its proprietary mesenchymal lineage cell therapy technology platforms. The Company’s Remestemcel-L is mesenchymal lineage stromal cell product platform and is in late-stage development for treatment of systemic inflammatory diseases, including Pediatric steroid refractory acute Graft versus Host Disease (SR-aGVHD), acute respiratory distress syndrome (ARDS) and Biologic refractory inflammatory bowel disease. Its Rexlemestrocel-L is mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of advanced chronic heart failure (CHF) and chronic low back pain (CLBP) due to degenerative disc disease. Two products are commercialized in Japan and Europe by the Company’s licensees, and it has a commercial partnership in Europe and China for certain Phase III assets.

Contact Information

Headquarters: L 38 55 Collins StMELBOURNE, VIC, Australia 3000
Phone: ---
Fax: ---

Executives

Non-Executive Independent Chairman of the Board: Jane Bell
Chief Executive Officer, Executive Director: Silviu Itescu
Non-Executive Independent Vice Chairman of the Board: William Burns
Interim Chief Financial Officer: Andrew Chaponnel
Chief Operating Officer: Dagmar Rosa-Bjorkeson

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Skip section

INK Company InsiderDetailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®.

Fundamentals Table
Market Cap	$843.1M
Revenue (TTM)	$7.5M
Shares Outstanding	114.2M
Dividend Yield	0.00%
Annual Dividend Rate	---
Ex-Dividend Date	01-01-01
Pay Date	01-01-01
Beta	3.47
EPS	$-1.44
Book Value	$12.34
P/E Ratio	-5.2x
Price/Sales (TTM)	112.9
Price/Cash Flow (TTM)	---
Operating Margin	-735.47%

*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Mesoblast Ltd
NASDAQ:MESOUnited States

Search Criteria

Charts

Recent News

Yesterday

Mesoblast Corporate Presentation at Investor Conference, from 8 hours ago by Dow Jones

Biotechnology Industry Peers

Company Information

Contact Information

Executives

Ratings

Reports

Fundamentals

Calendar